The use of zanamivir to treat influenza A and B infection after allogeneic stem cell transplantation.
The use of zanamivir in seven patients with influenza (three A and four B) post allograft is described. Inhaled zanamivir (10 mg twice daily) was continued from the diagnosis of influenza until excretion of virus ceased (median duration 15 days, range 5 to 44 days). There was no toxicity attributable to zanamivir and rapid resolution of influenza symptoms was seen. There was no mortality due to influenza in the seven patients. The good outcome of 30 previous patients with influenza post transplant is described. A randomised multicentre study would be required to demonstrate efficacy.
Johny
A A
AA
Department of Adult Bone Marrow Transplantation, United Bristol Healthcare Trust, Bristol Children's Hospital, Bristol, UK.
Clark
A
A
Price
N
N
Carrington
D
D
Oakhill
A
A
Marks
D I
DI
D000293:Adolescent; D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006146:Guanidines; D019337:Hematologic Neoplasms / Q000150:complications / Q000628:therapy; D006801:Humans; D009980:Influenza A virus; D009981:Influenza B virus; D007251:Influenza, Human / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D009190:Myelodysplastic Syndromes / Q000150:complications / Q000628:therapy; D011714:Pyrans; D012794:Sialic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D033581:Stem Cell Transplantation / Q000009:adverse effects*; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D053243:Zanamivir
D000998:Antiviral Agents; D006146:Guanidines; D011714:Pyrans; D012794:Sialic Acids; D053243:Zanamivir